Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The tumor microenvironment and immune responses in prostate cancer patients
J. Kwon, Richard J. Bryant, Ellen Parkes
Endocrine Related Cancer (2021) Vol. 28, Iss. 8, pp. T95-T107
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Association between circulating immune cells and the risk of prostate cancer: a Mendelian randomization study
Xuexue Hao, Congzhe Ren, Hang Zhou, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 14
Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics
Luiz Paulo Chaves, Camila Morais Melo, Fabiano Pinto Saggioro, et al.
Genes (2021) Vol. 12, Iss. 12, pp. 1900-1900
Open Access | Times Cited: 48
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
Sara Elena Rebuzzi, Pasquale Rescigno, Fabio Catalano, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1245-1245
Open Access | Times Cited: 34
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment
Duocai Li, Weidong Xu, Yifan Chang, et al.
Acta Biochimica et Biophysica Sinica (2023) Vol. 55, Iss. 6, pp. 956-973
Open Access | Times Cited: 17
Celloscope: a probabilistic model for marker-gene-driven cell type deconvolution in spatial transcriptomics data
Agnieszka Geras, Shadi Darvish Shafighi, Kacper Domżał, et al.
Genome biology (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 15
Emerging Immunotherapy Approaches for Treating Prostate Cancer
Lingbin Meng, Yuanquan Yang, Amir Mortazavi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 14347-14347
Open Access | Times Cited: 13
The impact of the P2X7 receptor on the tumor immune microenvironment and its effects on tumor progression
Yu-ting Zou, Jinyuan Li, Jun-yi Chai, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 707, pp. 149513-149513
Closed Access | Times Cited: 4
Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives
Xiaoya Li, Fang Yang, Meijing Wang, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Assessment of Immune Cell Populations in the Peripheral Blood of Patients With Metastatic Prostate Cancer
Vanessa Pérez, Patrícia Corredeira, Ana Cavaco, et al.
Cureus (2025)
Open Access
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
Razia Rahman, Luke A. Selth
Translational Oncology (2025) Vol. 55, pp. 102378-102378
Closed Access
Stimuli-responsive smart nanomaterials for theranostics of urological cancers
Yi Xu, Madineh Moradialvand, Francesca Della Sala, et al.
Coordination Chemistry Reviews (2025) Vol. 539, pp. 216745-216745
Closed Access
Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?
Gunhild von Amsberg, Winfried Alsdorf, Panagiotis Karagiannis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2569-2569
Open Access | Times Cited: 18
Extracellular vesicles and prostate cancer management: a narrative review
Fumihiko Urabe, Yuta Yamada, Shutaro Yamamoto, et al.
Translational Andrology and Urology (2024) Vol. 13, Iss. 3, pp. 442-453
Open Access | Times Cited: 3
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration–Resistant Prostate Cancer
Ana M. Aparicio, Rebecca S. Tidwell, Shalini S. Yadav, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 13, pp. 2751-2763
Closed Access | Times Cited: 3
Genetic variations in immune mediators and prostate cancer risk: A field synopsis with Bayesian calculations
Matheus Santos Freire, André Victor de Oliveira Monteiro, Tayane Moura Martins, et al.
Cytokine (2024) Vol. 179, pp. 156630-156630
Closed Access | Times Cited: 3
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer
Teresa Alonso‐Gordoa, Michael Goodman, Christof Vulsteke, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103446-103446
Open Access | Times Cited: 3
Approaches for boosting antitumor immunity in prostate cancer therapy: A comprehensive review on drugs, products, and nanoparticles
Diandian Chen, Yili Hu
Journal of Drug Delivery Science and Technology (2023) Vol. 89, pp. 105048-105048
Closed Access | Times Cited: 8
RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy
Zeyu Han, Xianyanling Yi, Jin Li, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 5, pp. 188961-188961
Closed Access | Times Cited: 7
Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer
Xiaolin Liu, Kunming Wang
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 7
Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment
Jakub Karwacki, Aleksander Kiełbik, Wojciech Szlasa, et al.
Cells (2022) Vol. 11, Iss. 18, pp. 2793-2793
Open Access | Times Cited: 12
It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective
Anniek Zaalberg, Elisabeth Pottendorfer, Wilbert Zwart, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 294-294
Open Access | Times Cited: 2
Comprehensive scRNA-seq analysis to identify new markers of M2 macrophages for predicting the prognosis of prostate cancer
Yitian Ou, Chengxing Xia, Chunwei Ye, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 2
Ipilimumab with Nivolumab in molecular-Selected patients with castration-resistant PRostate cancer: primary analysis of the Phase 2 INSPIRE trial
Sandra van Wilpe, Iris S. H. Kloots, P.H.J. Slootbeek, et al.
Annals of Oncology (2024)
Open Access | Times Cited: 2
Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
Wenqiang Qi, Yongheng Zhou, Zhifeng Liu, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
Andrea Marchetti, Elisa Tassinari, Matteo Rosellini, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 3, pp. 231-244
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top